INTRODUCTION
============

The use of extracorporeal membrane oxygenation (ECMO) support has increased in recent years,^([@r1])^ especially following the pandemic of influenza A (H1N1) virus pneumonitis.^([@r2]-[@r4])^ Although the results of previous randomized trials in which ECMO was used for respiratory support are inconclusive,^([@r5],[@r6])^ new technologies^([@r7])^ associated with the application of ultraprotective mechanical ventilation^([@r8])^ have improved survival and the quality of life when ECMO is used for patients with severe respiratory failure.^([@r9],[@r10])^

The high cost of the training and support required for ECMO use may have a negative economic impact, especially in developing countries.^([@r11])^ However, the high cost of the initial installation of the system is compensated for by its low cost of maintenance and the good outcomes obtained when ECMO support is used with adequate staff training, making this therapy cost-effective in developed countries^([@r9],[@r12])^ and potentially cost-effective in developing countries.^([@r13])^

Considering that ensuring the availability of appropriate staff in health centers with a relatively small occupancy rate may increase the cost of extracorporeal support, ECMO-equipped transport to specialized centers has been made available at an acceptable cost, with high survival rates and improvement in the quality of life.^([@r4],[@r9])^

Considering the importance of transport with ECMO, the objective of this study was to characterize the transport performed by our team in the State of São Paulo since 2011.

METHODS
=======

Data were retrieved from a prospectively collected database. The analysis of the database was assessed and approved by the Research Ethics Committee of the *Hospital das Clínicas* of the *Faculdade de Medicina* of the *Universidade de São Paulo* (USP) (number 107,443), and the requirement for informed consent was waived. Data on each patient were collected as previously described^([@r14],[@r15])^ using an online worksheet in the REDCap system.^([@r16])^

The contact was made by telephone by a local team member. Data were stored in an online spreadsheet. The severity of the patient\'s condition was determined, and the indications and contraindications for extracorporeal support were analyzed. The indication and contraindication criteria were previously described by our group.^([@r17])^ These criteria were modified slightly because the initial results were suboptimal due to occasional problems in the initial experience.^([@r14],[@r18]-[@r20])^ The current criteria are described in the Supplementary Material. Although the contraindication criteria were restrictive, special situations that generated doubts were discussed by our group. In cases in which the indication criteria were fulfilled or in which there were doubts, the remaining members of the team were contacted, and the final decision on whether or not to undertake support was made by the team as a whole.

The rescue team was composed of at least three professionals, of whom at least two were physicians (the third professional was a physician, a nurse, or a physical therapist). All the professionals who formed the team were trained to operate the system and to engage in open and direct communication with patients, relatives, and caregivers.

All the professionals made an initial assessment of the patients. When there was agreement about the indication, the two physicians were responsible for cannulation, and the third professional was responsible for communication with the patient\'s relatives and for equipment assembly, including priming the system.

Because an adequate transport system was not available, the requesting center was responsible for transporting the hospital staff to the requested location by ambulance or private transport. The team was responsible for carrying some equipment on the mission, including an ECMO system, a voltage stabilizer for the ECMO pump, two infusion pumps, a noninvasive blood pressure measurement system, and an oximeter. The transport of these items was confirmed using a checklist before departure for the mission. The remaining monitoring and support were provided by the ambulance in charge of the return transport.

Initial support, initial patient stabilization, and migration to protective/ultraprotective ventilation were performed in the presence of all three professionals. The stepwise technique used in this process was previously described.^([@r14])^ The ECMO system included a polymethylpentene membrane oxygenator connected to the following centrifugal pumps: (1) Rotaflow/Jostra Quadrox-D/Permanent Life Support (PLS; Maquet Cardiopulmonary AG, Hirrlingen, Germany), and (2) a BioPump with campanula and Affinity^TM^ circuit (Medtronic Inc, MN, USA) with a BIOCUBE 6000 membrane (Nipro Ltda, Sorocaba, São Paulo, Brazil).

Ambulances could be used to transport critical patients provided these vehicles had a mechanical ventilator capable of delivering at least 10cmH~2~O of positive end expiratory pressure and an inverter with a power of at least 2,000 watts. The latter feature was requested because less powerful inverters were not able to keep the ECMO pump working together with the other required devices. Team workload was reduced during transport by not carrying the ECMO thermoregulator and by carefully keeping the ambulance air conditioner off to avoid excessive cooling of the patient.

Statistical analysis
--------------------

The data were considered nonparametric because of the small sample size and are reported as the median \[25^th^ - 75^th^ percentile\] if quantitative and as the number of occurrences and percentages if qualitative. The comparisons between the groups presented in the tables were performed using the Mann-Whitney test for quantitative data and Fisher\'s exact test for qualitative data. The confidence interval of the survivor ratio was calculated according to the method described by the Association of Public Health Observatories^([@r21])^ using R software for calculations and graph creation.^([@r22])^

RESULTS
=======

The ECMO program was initiated in 2011, and the transport of ECMO patients began in the same year.^([@r14])^ A flowchart of the 28 requests for extracorporeal support outside the referral hospitals is shown in figure 1S. The first seven patients in this series were described in another publication.^([@r15])^ During the six years of the program, 18 patients in the state of São Paulo were rescued and transported with ECMO support by our team. Seventeen patients received exclusive respiratory support (veno-venous - VV configuration), and one patient received respiratory and cardiovascular support (veno-arterial - VA configuration). A profile of the patients is shown in [table 1](#t1){ref-type="table"}. The characteristics of the patients shortly before initiation of the support are shown in [table 2](#t2){ref-type="table"}. The Respiratory ECMO Survival Prediction Score (RESP score) and the tidal volume in pre-ECMO mechanical ventilation differed significantly in survivors and nonsurvivors. The data on the rescue missions and complications during transport are shown in [table 3](#t3){ref-type="table"}. The referral hospitals were *Hospital Sírio Libanês* (two patients), *Hospital TotalCor* (two patients), and the *Hospital das Clínicas* of São Paulo (14 patients).

###### 

General characteristics of patients transported with extracorporeal membrane oxygenation support

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                                            All patients\       Survivors\          Nonsurvivors\       p value[\*](#TFN17){ref-type="table-fn"}
                                                                             (n = 18)            (n = 13)            (N = 5)             
  -------------------------------------------------------------------------- ------------------- ------------------- ------------------- ------------------------------------------
  Age (years)                                                                29 \[25 - 31\]      28 \[25 - 31\]      29 \[27 - 31\]      0.621

  Female                                                                     11 (61)             9 (69)              2 (40)              0.326

  SAPS 3                                                                     84 \[68 - 92\]      84 \[66 - 88\]      80 \[73 - 95\]      0.961

  Mortality predicted in South America (%)[†](#TFN18){ref-type="table-fn"}   89 \[66 - 94\]      89 \[62 - 92\]      86 \[76 - 95\]      1.000

  Mortality predicted in Europe (%)[†](#TFN18){ref-type="table-fn"}          76 \[46 - 85\]      76 \[42 - 81\]      71 \[58 - 88\]      0.961

  SOFA                                                                       13 \[9 - 16\]       14 \[10 - 16\]      13 \[9 - 13\]       0.584

  Weight (kg)                                                                74 \[55 - 84\]      72 \[50 - 78\]      84 \[60 - 84\]      0.298

  Height (cm)                                                                165 \[160 - 185\]   165 \[160 - 170\]   180 \[160 - 185\]   0.344

  Associated clinical conditions                                                                                                         0.920

      Systemic arterial hypertension                                         2 (11)              1 (8)               1 (20)               

      Diabetes mellitus                                                      1 (9)               1 (8)               0 (0)                

      Gestational complications                                              1 (9)               1 (8)               0 (0)                

      Postpartum complications                                               3 (17)              3 (38)              0 (0)                

      Systemic lupus erythematosus                                           1 (9)               1 (8)               0 (0)                

      HIV/AIDS                                                               1 (9)               0 (0)               1 (20)               

  Etiological diagnoses                                                                                                                  0.810

      Alveolar hemorrhage due to lupus                                       1 (9)               1 (8)               0 (0)                

      Leptospirosis                                                          3 (17)              3 (38)              0 (0)                

      H3N2 Influenza A virus                                                 1 (9)               0 (0)               1 (20)               

      H1N1 Influenza A virus                                                 3 (17)              2 (38)              1 (20)               

      Influenza B virus                                                      1 (9)               1 (8)               0 (0)                

      Varicella zoster virus                                                 1 (9)               1 (8)               0 (0)                

      Respiratory syncytial virus                                            1 (9)               1 (8)               0 (0)                

      Coronavirus                                                            1 (9)               1 (8)               0 (0)                

      Epstein-Barr virus                                                     1 (9)               1 (8)               0 (0)                

      Nosocomial pneumonia                                                   1 (9)               1 (8)               0 (0)                

      Aspiration pneumonia                                                   1 (9)               0 (0)               1 (20)               

      Necrotizing pneumonia                                                  1 (9)               0 (0)               1 (20)               

      Pelvic septic thrombophlebitis                                         1 (9)               1 (8)               0 (0)                

      *Pneumocystis jirovecii*                                               1 (9)               0 (0)               1 (20)               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SAPS 3 - Simplified Acute Physiology Score 3; SOFA - Sequential Organ Failure Assessment Score.

Value of comparison between survivors and nonsurvivors;

calculation was performed using the logit of SAPS 3 for South America and Western Europe, respectively. The results are expressed as the median \[interquartile 25 - 75\] or the number (%).

###### 

Respiratory and hemodynamic characteristics of patients who received extracorporeal membrane pre-oxygenation support

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                      All patients\           Survivors\              Nonsurvivors\             p value[\*](#TFN20){ref-type="table-fn"}
                                       (n = 18)                (n = 13)                (N = 5)                   
  ------------------------------------ ----------------------- ----------------------- ------------------------- ------------------------------------------
  Murray score                         3.7 \[3.0 - 4.0\]       3.5 \[3.0 - 4.0\]       3.8 \[3.0-4.0\]           0.448

  Mechanical ventilation time (days)   7 \[1 - 11\]            5 \[1 - 8\]             8 \[7-15\]                0.113

  ICU time (days)                      7 \[2 - 11\]            5 \[1 - 9\]             8 \[8-15\]                0.199

  RESP score                           0.00 \[-2.00 - 2.00\]   1.50 \[-0.25 - 3.25\]   -2.00 \[-3.00 - -1.00\]   0.023

  Survival rate (RESP) (%)             50 \[40 - 60\]          58 \[48 - 69\]          40 \[35 - 45\]            0.034

  SAVE score                           0.00                    0.00                    \-\--                     \-\--

  Survival rate (SAVE) (%)             40                      40                      \-\--                     \-\--

  Mechanical ventilation                                                                                          

      Pressure-controlled mode         14 (78)                 10 (77)                 4 (80)                    1.000

      Volume-controlled mode           4 (22)                  3 (23)                  1 (20)                     

      PEEP (cmH~2~O)                   14 \[10 - 18\]          12 \[10 - 15\]          17 \[13 - 18\]            0.269

      FiO~2~ (%)                       100 \[100 - 100\]       100 \[100 - 100\]       100 \[100 - 100\]         0.288

      Tidal volume (mL/kg)             4 \[4 - 6\]             5 \[4 - 6\]             3 \[3 - 4\]               \< 0.001

  Respiratory rate (ipm)               28 \[25 - 35\]          28 \[25 - 35\]          28 \[28 - 35\]            0.723

  Plateau pressure (cmH~2~O)           33 \[30 - 35\]          34 \[30 - 35\]          32 \[31 - 35\]            0.960

  Blood gas analysis                                                                                              

      pH                               7.27 \[7.08 - 7.35\]    7.27 \[7.09 - 7.35\]    7.10 \[7.00 - 7.34\]      0.622

      PaO~2~ (mmHg)                    54 \[38 - 60\]          58 \[39 - 65\]          50 \[45 - 60\]            0.882

      PaCO~2~ (mmHg)                   61 \[46 - 90\]          53 \[42 - 80\]          90 \[49 - 90\]            0.429

      SBE (mEq/L)                      1.5 \[-2.5 - 4.8\]      1.0 \[-3.0 - 6.0\]      2.0 \[0.0 - 4.0\]         0.805

  Lactate (mEq/L)                      2.7 \[2.2 - 3.9\]       2.7 \[2.2 - 3.3\]       2.7 \[2.7 - 4.4\]         0.692

  P/F ratio (mmHg)                     55 \[39 - 60\]          60 \[39 - 65\]          50 \[45 - 60\]            0.657

  Salvage therapy                                                                                                 

      Alveolar recruitment             15 (84)                 10 (77)                 5.100                     0.638

      Nitric oxide                     2 (11)                  0 (0)                   2 (40)                    0.114

      Prone position                   12 (67)                 7 (54)                  5.100                     0.193

      Curarization                     15 (84)                 10 (77)                 5.100                     0.638

      TGI                              2 (11)                  0 (0)                   2 (40)                    1.000

      Corticosteroids                  12 (67)                 8 (62)                  4 (40)                    0.852

  Hemodynamic support                                                                                             

      Noradrenaline                    16 (89)                 12 (92)                 4 (80)                    1.000

      Vasopressin                      4 (22)                  1 (8)                   3 (60)                    0.078

      Adrenaline                       3 (17)                  1 (8)                   2 (40)                    1.000

      Dobutamine                       3 (17)                  3 (23)                  0 (0)                     0.638
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

ICU - intensive care unit; RESP score - Respiratory ECMO Survival Prediction Score; SAVE score - Survival After Veno-Arterial-ECMO Score; PEEP - positive end-expiratory pressure; FiO~2~ - fraction of inspired oxygen; PaO~2~ - partial pressure of oxygen; PaCO~2~ - partial pressure of carbon dioxide; SBE - standard base excess; P/F ratio - PaO~2~/FiO~2~ ratio; TGI - tracheal gas insufflation.

Value of comparison between survivors and nonsurvivors. The results are expressed as the median \[interquartile 25 - 75\] or the number (%).

###### 

Characteristics of missions and transportation

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                All patients\       Survivors\          Nonsurvivors\       p value[\*](#TFN22){ref-type="table-fn"}
                                                 (n = 18)            (n = 13)            (N = 5)             
  ---------------------------------------------- ------------------- ------------------- ------------------- ------------------------------------------
  Hospital of origin                                                                                          

      Public                                     13 (72)             9 (69)              4 (80)              0.057

      Private                                    5 (28)              4 (31)              1 (20)               

  Referral hospital                                                                                           

      Public                                     14 (78)             10 (77)             4 (80)              1.000

      Private                                    4 (22)              3 (23)              1 (20)               

  Mission time (minutes)                         360 \[308 - 431\]   360 \[300 - 420\]   420 \[345 - 435\]   0.520

  Distance traveled (km)                         39 \[15 - 82\]      40 \[12 - 90\]      37 \[23 - 40\]      1.000

  Professionals involved                                                                                      

      Nurses (number per mission)                1 \[0 - 2\]         1 \[0 - 2\]         1 \[1 - 2\]         0.675

      Doctors (number per mission)               3 \[2 - 3\]         3 \[2 - 3\]         2 \[2 - 3\]         0.437

      Physical therapists (number per mission)   1 \[0 - 1\]         1 \[0 - 1\]         1 \[0 - 1\]         1.000

  Transportation vehicle                                                                                      

      Ambulance                                  17 (94)             12 (92)             5.100               1.000

      Helicopter                                 1 (6)               1 (8)               0 (0)                

  Complications                                                                                               

      Insufficient power                         2 (11)              1 (8)               1 (20)              1.000

      SpO~2~ \< 70%                              2 (11)              2 (16)              0 (0)               0.890

      SpO~2~ \< 85%                              4 (22)              2 (16)              2 (40)              0.900

      Hemodynamic worsening                      0 (0)               0 (0)               0 (0)               1.000

      Temperature \< 35 ºC                       1 (6)               1 (8)               0 (0)               0.900
  -----------------------------------------------------------------------------------------------------------------------------------------------------

SpO~2~ - blood oxygen saturation.

Value of comparison between survivors and nonsurvivors. The results are expressed as the number (%) or the median \[interquartile 25 - 75\].

The data on the extracorporeal support are shown in [table 4](#t4){ref-type="table"}. Respiratory support was provided using the femoral-jugular configuration, and veno-arterial support (one case) was provided using the femoral-femoral configuration. The venous cannulae were 21 - 22 Fr, and the arterial cannulae were 16 - 19 Fr. Apart from veno-arterial cannulation, anticoagulation was started upon patient arrival at the referral hospital. Five patients did not use anticoagulation at any time because of pulmonary hemorrhage (four cases) or the presence of cerebral vasculitis with hemorrhagic areas (one case). None of the evaluated patients had a change of itinerary or a change in the support configuration related to initial cannulation. The final results are shown in [table 5](#t5){ref-type="table"}. The minimum and maximum duration of support was 3 and 60 days, respectively. Of the 18 patients, 13 (72%, 95%CI 49 - 88) survived to hospital admission (Figure 2S). Of the survivors, only one patient needed dialysis after hospital admission, and none required home oxygen therapy. The individual patient data are presented in table 1S.

###### 

Support and complications of patients in the intensive care unit

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                                        All patients\            Survivors\               Nonsurvivors\            p value[\*](#TFN24){ref-type="table-fn"}
                                                                         (n = 18)                 (n = 13)                 (N = 5)                  
  ---------------------------------------------------------------------- ------------------------ ------------------------ ------------------------ ------------------------------------------
  Cannulation                                                                                                                                        

      Veno-venous ECMO                                                   17 (94)                  12 (92)                  5.100                    1.000

      Veno-arterial ECMO                                                 1 (6)                    1 (8)                    0 (0)                     

  Initial settings for ECMO                                                                                                                          

      Blood flow (mL/min)                                                4725 \[4.300 - 5.498\]   4500 \[4.300 - 5.400\]   5000 \[4.300 - 6.400\]   0.521

      Sweep flow (L/min)                                                 6.0 \[4.0 - 8.0\]        4,5 \[4.0 - 8.0\]        6.0 \[6.0 - 10.0\]       0.136

      FiO~2~ (%)                                                         100 \[100 - 100\]        100 \[100 - 100\]        100 \[100 - 100\]        1.000

  Initial fan settings                                                                                                                               

      PSV mode                                                           3 (17)                   3 (23)                   0 (0)                    0.372

      PCV mode                                                           14 (78)                  9 (69)                   5.100                     

      APRV mode                                                          1 (6)                    1 (8)                    0 (0)                     

  Tidal volume (mL/kg)                                                   2.1 \[0.89 - 2.71\]      2.33 \[0.80 - 2.93\]     0.95 \[0.91 - 2.20\]     0.460

  PEEP (cmH2O)                                                           10 \[10 - 10\]           10 \[10 - 10\]           10 \[10 - 12\]           0.105

  Plateau pressure (cmH~2~O)                                             20 \[20 - 20\]           20 \[20 - 20\]           20 \[20 - 25\]           0.088

  FiO~2~ (%)                                                             30 \[30 - 38\]           30 \[30 - 30\]           30 \[30 - 60\]           0.736

  Respiratory rate (inspirations/min.)                                   10 \[10 - 10\]           10 \[10 - 10\]           10 \[10 - 10\]           0.543

  Post-ECMO blood gas analysis                                                                                                                       

      pH                                                                 7.39 \[7.37 - 7.44\]     7.39 \[7.36 - 7.40\]     7.46 \[7.40 - 7.51\]     0.080

      PaO~2~ (mmHg)                                                      61 \[52 - 68\]           62 \[52 - 68\]           53 \[49 - 65\]           0.375

      PaCO~2~ (mmHg)                                                     38 \[36 - 42\]           40 \[36 - 44\]           36 \[33 - 36\]           0.048

      SBE (mEq/L)                                                        1.3 \[-0.6 - 4.2\]       1.0 \[-0.5 - 4.0\]       1.6 \[-3.4 - 8.4\]       0.921

  PaO~2~ \< 40mmHg in ECMO[\#](#TFN25){ref-type="table-fn"}              5 (28)                   3 (23)                   2 (40)                   0.896

  Positive blood cultures at admission                                                                                                               

      *Candida sp.*                                                      3 (17)                   2 (15)                   1 (20)                   1.000

      *Pseudomonas aeruginosa*                                           2 (11)                   1 (8)                    1 (20)                   0.490

      *Klebsiella pneumoniae*                                            1 (6)                    0 (0)                    1 (20)                   0.278

      *Proteus mirabilis*                                                1 (6)                    1 (8)                    0 (0)                    1.000

  Renal replacement therapy                                                                                                                          

      Continuous                                                         10 (56)                  7 (54)                   3 (60)                   1.000

      Intermittent                                                       6 (33)                   6 (46)                   0 (0)                    0.192

      Not used                                                           8 (44)                   6 (46)                   2 (40)                   1.000

  Nosocomial infections acquired upon arrival at the referral hospital                                                                               

      PAV                                                                1 (6)                    1 (8)                    0 (0)                    0.900

      UTI                                                                1 (6)                    0 (0)                    1 (20)                   0.278

      Catheter infection                                                 0 (0)                    0 (0)                    0 (0)                    1.000
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ECMO - extracorporeal membrane oxygenation; FiO~2~ - fraction of inspired oxygen; PSV - pressure-supported ventilation; PCV - pressure-controlled ventilation; APRV - airway pressure release ventilation; PEEP - positive-end expiratory pressure; PaO~2~ - partial oxygen pressure; PaCO~2~ - partial carbon dioxide pressure; SBE - standard base excess; VAP - ventilator-associated pneumonia; UTI - urinary tract infection.

Value of comparison between survivors and nonsurvivors;

persistent for more than 6 hours. The results are expressed as the number (%) or the median \[interquartile 25 - 75\].

###### 

Results of transportation

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                                                    All patients\   Survivors\     Nonsurvivors\   p value[\*](#TFN27){ref-type="table-fn"}
                                                                                     (n = 18)        (n = 13)       (N = 5)         
  ---------------------------------------------------------------------------------- --------------- -------------- --------------- ------------------------------------------
  Hospital discharge                                                                 13 (72)         13 (100)       0 (0)           \-\--

  ICU discharge                                                                      13 (72)         13 (100)       0 (0)           \-\--

  ECMO weaning                                                                       15 (84)         13 (100)       2 (40)          \-\--

  MV weaning                                                                         13 (72)         13 (100)       0 (0)           \-\--

  Tracheostomized                                                                    5 (28)          5 (38)         0 (0)           \-\--

  ECMO time (days)                                                                   6 \[4-9\]       5 \[4-9\]      6 \[3-10\]      1.000

  MV time (days)                                                                     7 \[6-18\]      7 \[6-12\]     6 \[5-20\]      0.580

  ICU time (days)                                                                    15 \[10-21\]    16 \[12-21\]   6 \[3-20\]      0.289

  Length of hospitalization (days)                                                   25 \[14-50\]    28 \[24-50\]   6 \[3-20\]      0.084

  Oxygen dependence after discharge                                                  0 (0)           0 (0)          0 (0)           \-\--

  Need for dialysis after discharge                                                  1 (6)           1 (8)          0 (0)           \-\--

  Cause of death                                                                                                                     

      Brain death[†](#TFN28){ref-type="table-fn"} [‡](#TFN29){ref-type="table-fn"}   \-\--           \-\--          2 (40)          \-\--

      Multiple organ dysfunction syndrome                                            \-\--           \-\--          2 (40)          \-\--

      Irreversible pulmonary fibrosis[¶](#TFN30){ref-type="table-fn"}                \-\--           \-\--          1 (20)          \-\--
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ICU - intensive care unit; ECMO - extracorporeal membrane oxygenation; MV - mechanical ventilation.

Value of comparison between survivors and nonsurvivors;

patients with support withdrawal;

one patient with extensive brain hemorrhage and one patient with diffuse ischemia and secondary bleeding;

irreversible fibrosis characterized by the complete absence of vascular scaffold in open lung biopsy after 60 days of support with extracorporeal membrane oxygenation and without signs of improvement. The results are expressed as number (%) or median \[interquartile 25-75\].

DISCUSSION
==========

In this case series of 18 severe patients transported to specialized centers with ECMO support in São Paulo, the rate of complications was low, and hospital survival was 72%. Of the patients who were discharged from the hospital, only one needed renal replacement therapy, and none required home oxygen therapy.

Fewer than 2% of the patients admitted to the intensive care unit (ICU) suffered from severe respiratory failure. Of these, fewer than 0.5% were refractory to protective mechanical ventilation and salvage therapy for hypoxemia and severe hypercapnia^([@r23])^ and sometimes required ECMO support. The low rate of very severe patients limits the ability to maintain a team to perform ECMO support in all ICUs. Therefore, in developed countries, transport with installed ECMO support was used to reduce the risk of transportation to specialized centers, and the patient survival rate was 62% (95%CI 57 - 68%).^([@r4],[@r15])^ In our series, hospital survival was 72% (95%CI 49 - 88%), in agreement with the data reported in the literature.^([@r15])^

These results are attributed to two main causes. The first is the use of more rigorous inclusion and exclusion criteria, which resulted in restricting the use of ECMO to highly selected patients because ECMO support seems to have a survival benefit with improved quality of life for patients with few comorbidities and few acute dysfunctions.^([@r9],[@r24])^ In addition, the application of rescue therapy, such as the use of the prone position before ECMO, is essential whenever possible because this therapy is inexpensive and there is strong evidence that its use improves patient survival.^([@r25])^ Second, the use of ECMO support can be optimized by providing adequate training and experience to the multidisciplinary team^([@r18])^ and by the involvement of professionals who possess comprehensive knowledge of emergency care and possible complications during ECMO support.^([@r26]-[@r28])^

In our study, the comparison of survivors and nonsurvivors should be considered preliminary because of the small sample size. However, certain factors should be considered. The initial tidal volume of the patients who died was lower than that of those who survived, suggesting greater severity of lung injuries and poorer lung compliance in the former. The Simplified Acute Physiology Score 3 (SAPS 3) did not differ in the two groups, and the RESP score,^([@r29])^ which was used in decision-making, was higher in survivors. Although the RESP score was developed as a means of predicting patient survival under ECMO support, other scores that were developed to predict patient survival better address other organic functions and may therefore be more accurate.^([@r30])^ The Survival After Veno-Arterial ECMO Score (SAVE score) was described, but the effects of using this score were not analyzed because it was used in only one case.

Another relevant factor in our sample of nonsurvivors was that the partial pressure decrease in carbon dioxide (PaCO~2~) from pre- to post-ECMO was critical. This characteristic is known to be related to higher patient mortality in ECMO.^([@r31])^ This factor may have contributed to the deaths of two patients who progressed to brain death while in the ICU. This outcome alerted us to the importance of the careful initiation of extracorporeal ventilation, especially in hypercapnic patients with gas/blood flow \< 1, to ensure a smaller initial decrease in PaCO~2~.

The most serious problems that arose during transport were addressed as follows. (1) Energy failure was avoided by using a hand pump for one patient and by turning off the warning lights for another patient, and the ambulance power inverter was dedicated to the operation of the pump. (2) Only decreases in oxygen saturation \< 85% and \> 70% were observed. These dessaturations occurred because of the severity of lung injury, associated with a cardiac output. Severe hypoxemia may occur during the acute phase of respiratory support and sometimes needs to be tolerated by the team;^([@r32])^ although this complication may not directly affect survival or cognitive outcome, it indicates the severity of the patient\'s condition.^([@r33])^

Although the sample described in this study does not provide new data, it represents the first case series of patients transported in ECMO in Brazil. However, the results of this study should be viewed with caution for several reasons. First, because the sample size was small, it was not possible to perform a multivariate analysis. Second, the results of the analyses are preliminary and should not be used to change procedures at the bedside. Third, generalization of the results reported here to other centers should be made with caution because the number of ECMO support cases per year was low (5 - 10). Fourth, the indications were restricted to a small subset of patients.

Under certain conditions, ECMO can be an effective and cost-effective therapy. The results of this case series demonstrate that this approach can be effective when restrictive indications are followed, adequate intensive care is provided to avoid complications during hospitalization, and the staff involved in patient care are continuously trained to enable them to treat life-threatening complications that may occur during ECMO support. In our opinion, this can only be achieved in a few centers while maintaining the cost-effectiveness of therapy.

CONCLUSIONS
===========

Transport of severely ill patients with extracorporeal respiratory support in a Brazilian state was feasible and did not result in severe complications. Despite the small sample size, patient survival to hospital admission was similar to that reported in the literature.

Supplementary Material
======================

###### 

Click here for additional data file.
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